Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder

Shizuo Yamada, Junko Chimoto, Mizuki Shiho, Takashi Okura, Kana Morikawa, Hirokazu Wakuda and Kazumasa Shinozuka
Journal of Pharmacology and Experimental Therapeutics May 2021, 377 (2) 201-206; DOI: https://doi.org/10.1124/jpet.120.000301
Shizuo Yamada
Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (S.Y., J.C.); Laboratory of Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan (M.S., T.O.); and Department of Pharmacology II, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Japan (K.M., H.W., K.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junko Chimoto
Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (S.Y., J.C.); Laboratory of Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan (M.S., T.O.); and Department of Pharmacology II, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Japan (K.M., H.W., K.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mizuki Shiho
Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (S.Y., J.C.); Laboratory of Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan (M.S., T.O.); and Department of Pharmacology II, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Japan (K.M., H.W., K.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Okura
Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (S.Y., J.C.); Laboratory of Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan (M.S., T.O.); and Department of Pharmacology II, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Japan (K.M., H.W., K.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kana Morikawa
Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (S.Y., J.C.); Laboratory of Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan (M.S., T.O.); and Department of Pharmacology II, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Japan (K.M., H.W., K.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirokazu Wakuda
Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (S.Y., J.C.); Laboratory of Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan (M.S., T.O.); and Department of Pharmacology II, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Japan (K.M., H.W., K.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazumasa Shinozuka
Center for Pharma-Food Research (CPFR), Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (S.Y., J.C.); Laboratory of Pharmaceutics, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan (M.S., T.O.); and Department of Pharmacology II, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Japan (K.M., H.W., K.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The selective β3-adrenoceptor agonist mirabegron, an established alternative to antimuscarinic therapy for patients with overactive bladder, induces additional effects against receptors, transporters, and hepatic enzymes. The present study aimed to elucidate the effects of mirabegron on muscarinic receptors in the rat bladder using radioligand binding and functional assays. Mirabegron (0.1–100 μM) inhibited specific [N-methyl-3H]scopolamine methyl chloride binding in the bladder and other tissues of rats in a concentration-dependent manner. Binding affinity in the bladder was similar to that in the heart and significantly higher than those in the submaxillary gland and brain. Mirabegron induced the concentration-dependent relaxation of carbachol-induced contractions in the rat isolated bladder. Further analyses using a two-site model revealed that the relative quantities of high- and low-affinity components for mirabegron were 44.5% and 55.5%, respectively. Respective pEC50 values were 7.06 and 4.97. Based on the receptor binding affinity and pharmacokinetics of mirabegron, muscarinic receptor occupancy in the human bladder for 24 hours after the administration of a single oral dose of 50 mg mirabegron was 37%–76%. The present results demonstrate for the first time that mirabegron may relax the detrusor smooth muscle not only by β3-adrenoceptor activation but also muscarinic receptor blockade.

SIGNIFICANCE STATEMENT Mirabegron, the first selective β3-adrenoceptor agonist, represents an alternative to antimuscarinic agents for management of overactive bladder (OAB). The present study aimed to clarify whether mirabegron directly binds to muscarinic receptors and affects cholinergic agonist–induced contractions in rat urinary bladder and to predict muscarinic receptor occupancy in human bladder after oral administration of mirabegron. The results demonstrated that mirabegron therapy for patients with OAB may be due not only to β3-adrenoceptor activation but also muscarinic receptor blockade.

Footnotes

    • Received August 25, 2020.
    • Accepted February 12, 2021.
  • This work received no external funding.

  • The authors indicated no conflicts of interest.

  • Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 377 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 377, Issue 2
1 May 2021
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Antimuscarinic Effects of Mirabegron

Shizuo Yamada, Junko Chimoto, Mizuki Shiho, Takashi Okura, Kana Morikawa, Hirokazu Wakuda and Kazumasa Shinozuka
Journal of Pharmacology and Experimental Therapeutics May 1, 2021, 377 (2) 201-206; DOI: https://doi.org/10.1124/jpet.120.000301

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleDrug Discovery and Translational Medicine

Antimuscarinic Effects of Mirabegron

Shizuo Yamada, Junko Chimoto, Mizuki Shiho, Takashi Okura, Kana Morikawa, Hirokazu Wakuda and Kazumasa Shinozuka
Journal of Pharmacology and Experimental Therapeutics May 1, 2021, 377 (2) 201-206; DOI: https://doi.org/10.1124/jpet.120.000301
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Apigenin Relieves Hyperlipidemia
  • Exposure-Receptor Occupancy Relationships for mGlu5 NAMs
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics